DAFNA Capital Management as of Sept. 30, 2014
Portfolio Holdings for DAFNA Capital Management
DAFNA Capital Management holds 59 positions in its portfolio as reported in the September 2014 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Pharmacyclics | 13.1 | $13M | 111k | 117.43 | |
| Discovery Laboratories Com New | 10.6 | $11M | 5.7M | 1.84 | |
| AtriCure (ATRC) | 8.9 | $8.8M | 599k | 14.72 | |
| NxStage Medical | 5.1 | $5.0M | 384k | 13.13 | |
| Insulet Corporation (PODD) | 4.1 | $4.0M | 109k | 36.85 | |
| Auspex Pharmaceuticals | 3.9 | $3.9M | 152k | 25.67 | |
| Novadaq Technologies | 3.4 | $3.3M | 264k | 12.69 | |
| Ocera Therapeutics | 3.3 | $3.3M | 676k | 4.90 | |
| Derma Sciences Com Par $.01 | 3.2 | $3.2M | 385k | 8.33 | |
| Stereotaxis Com New (STXS) | 3.2 | $3.2M | 1.4M | 2.32 | |
| Protalix BioTherapeutics | 3.1 | $3.1M | 1.3M | 2.42 | |
| Aerie Pharmaceuticals | 3.0 | $3.0M | 145k | 20.69 | |
| Insulet Corp Note 2.000% 6/1 (Principal) | 2.7 | $2.7M | 2.4M | 1.11 | |
| BioSpecifics Technologies | 2.1 | $2.1M | 60k | 35.30 | |
| Threshold Pharmaceuticals Com New | 2.0 | $2.0M | 556k | 3.61 | |
| Clovis Oncology | 1.7 | $1.7M | 37k | 45.37 | |
| Cardica | 1.6 | $1.6M | 1.5M | 1.07 | |
| Biotelemetry | 1.6 | $1.6M | 236k | 6.71 | |
| XenoPort | 1.3 | $1.3M | 240k | 5.38 | |
| Uroplasty Com New | 1.2 | $1.2M | 486k | 2.50 | |
| Nuvasive Note 2.750% 7/0 (Principal) | 1.2 | $1.1M | 1.0M | 1.15 | |
| Spectranetics Corporation | 1.1 | $1.1M | 42k | 26.56 | |
| Venaxis | 1.1 | $1.1M | 658k | 1.66 | |
| Neurocrine Biosciences (NBIX) | 1.0 | $1.0M | 66k | 15.66 | |
| Galmed Pharmaceuticals SHS | 1.0 | $1.0M | 117k | 8.60 | |
| Johnson & Johnson (JNJ) | 1.0 | $1.0M | 9.4k | 106.60 | |
| Encision | 1.0 | $983k | 1.1M | 0.93 | |
| Syneron Medical Ord Shs | 0.9 | $911k | 91k | 10.02 | |
| Bluebird Bio (BLUE) | 0.9 | $897k | 25k | 35.88 | |
| Cutera (CUTR) | 0.9 | $896k | 89k | 10.10 | |
| Affimed Therapeutics B V | 0.8 | $756k | 120k | 6.30 | |
| BioCryst Pharmaceuticals (BCRX) | 0.8 | $747k | 76k | 9.78 | |
| Exactech | 0.7 | $724k | 32k | 22.89 | |
| Aastrom Biosciences Com Par$ | 0.7 | $681k | 239k | 2.85 | |
| Cytrx Corp Com Par $.001 | 0.6 | $572k | 225k | 2.54 | |
| Ampio Pharmaceuticals | 0.5 | $530k | 150k | 3.53 | |
| Caredx (CDNA) | 0.5 | $525k | 75k | 7.00 | |
| Intercept Pharmaceuticals In | 0.5 | $473k | 2.0k | 236.50 | |
| Oncothyreon | 0.4 | $413k | 215k | 1.92 | |
| RTI Biologics | 0.4 | $411k | 86k | 4.78 | |
| Fate Therapeutics (FATE) | 0.4 | $387k | 76k | 5.10 | |
| Masimo Corporation (MASI) | 0.4 | $372k | 18k | 21.26 | |
| Scynexis | 0.4 | $370k | 50k | 7.40 | |
| Lpath Com New | 0.4 | $362k | 103k | 3.52 | |
| Targacept | 0.3 | $339k | 134k | 2.53 | |
| Uniqure SHS (QURE) | 0.3 | $296k | 32k | 9.25 | |
| Celsus Therapeutics Sponsored Adr Ne | 0.3 | $268k | 44k | 6.10 | |
| Lumenis SHS CL B | 0.3 | $259k | 29k | 8.93 | |
| Achillion Pharmaceuticals | 0.3 | $259k | 26k | 9.96 | |
| Biolife Solutions Com New (BLFS) | 0.2 | $244k | 116k | 2.10 | |
| Intellipharmaceuticsintl Inc C | 0.2 | $219k | 73k | 3.01 | |
| Curis | 0.2 | $212k | 150k | 1.41 | |
| Genvec Com New | 0.2 | $208k | 100k | 2.08 | |
| Chembio Diagnostics Com New | 0.2 | $205k | 55k | 3.71 | |
| Tonix Pharmaceuticals Hldg C Com New | 0.2 | $171k | 25k | 6.84 | |
| Cynapsus Therapeutics | 0.2 | $149k | 281k | 0.53 | |
| Inspiremd Com New | 0.1 | $140k | 64k | 2.20 | |
| Globeimmune (GBIM) | 0.1 | $74k | 11k | 6.89 | |
| Retractable Technologies (RVP) | 0.1 | $58k | 20k | 2.90 |
